Table 1.

Demographic and clinicopathological characteristics of the study cohort.

Tumour location (n)			Gastroenteropancreatic neuroendocrine neoplasia (n = 215)							Lung NETs (n = 43)
Variable	Category		PNEN (n = 67)	SINEN (n = 40)	DNEN (n = 9)	GNEN G1/2 (n = 41)	GNEN G3 (n = 3)	RNEN (n = 45)	ANEN (n = 10)	BPC (n = 43)
Age	Mean		56	58	48	55	60	57	41	61
	Range		19–87	27–77	29–62	28–87	39–84	37–78	19–65	31–78
Gender	M:F		24:43:00	22:18	5:04	10:31	2:01	24:21:00	5:05	14:29
Function status	NF:F		58:09:00	25:15:00	9:00	41:00:00	3:00	45:00:00	10:00	41:02:00
Grade	G1a		33	31	7	31	0	42	9	27
	G2b		27	8	1	10	0	3	1	16
	G3 NET		2	1	0	0	1	0	0	N/A
	G3 NEC#		3	0	1	0	2	0	0	N/A
	No data		2	0	0	0	0	0	0	N/A
TNM stage	Localized	IND	23	2	2	24	1	37	9	19
		IPD	11	0	5	15	1	1	0	6
	Regional metastatic	IND	2	8	0	2	1	1	1	2
		IPD	8	6	2	0	0	1	0	8
	Distant metastatic	IND	0	1	0	0	0	0	0	0
		IPD	23	23	0	0	0	5	0	8
Disease status (RECIST 1.1)	Progressive		14	2	2	0	0	3	N/A	4
	Stable		28	27	5	24	3	4	N/A	18
Therapy at blood draw	SSA		27	22	0	0	0	5	0	7
	MTT		2	2	0	0	0	0	0	0
	Cx		0	0	0	0	0	0	0	1
Previous therapy	SSA		–	1	0	0	0	0	0	–
	Primary resection/LRT		44/6	27/4	3	33	2	45	9	39/1
	PRRT		11	11	0	0	0	1	0	2
	Cx		6	1	0	0	0	0	0	2
	Rx		3	0	0	0	0	0	0	1
	MTT		1	0	0	0	0	0	0	0

^aTC for BPC; ^bAC for BPC.

ANEN, appendiceal NEN; BPC, bronchopulmonary carcinoids; Cx, chemotherapy; DNEN, duodenal NEN;Function status: NF, non-functioning; F, functioning; Gender: m, Male; F, female; GNEN, gastric NEN; IND, image-negative disease; IPD, image-positive disease; LRT, locoregional therapy; MTT, molecular targeted therapy; N/A, not applicable; PRRT, peptide receptor radionuclide therapy; PNEN, pancreatic NEN;Rx, radiotherapy; RNEN, rectal NEN; SINEN, small intestine (midgut) NEN; SSA, somatostatin analogues.